(AMGN) Amgen Inc. BCG Matrix Research

MVASI, the bevacizumab biosimilar, keeps Amgen in a large oncology lane where switching from originators still drives volume. Bevacizumab has been used since 2004, and MVASI entered the U.S. in 2019, so it benefits from a deep, established demand base.

Oncology biologics remain a high-volume category, and biosimilar adoption keeps widening as payers push lower-cost options. That makes MVASI a clear Star: it sits in a growing market and gives Amgen meaningful share exposure.

• Bevacizumab market is mature, still large
• MVASI supports oncology biosimilar growth
• Switching pressure favors biosimilar volume
• Amgen gains scale in a key category

KANJINTI fits Amgen Inc. as a Star: it serves the HER2 oncology franchise, where trastuzumab biosimilars keep taking share even as the core market is mature. In 2025, that mix still matters because biosimilar uptake expands access and keeps pressure on legacy branded pricing.

Amgen Inc. benefits from a broad trastuzumab class with multiple biosimilar options, so KANJINTI is not a dead-growth asset. It is a growth-plus-share play, with value tied to ongoing conversion in breast and gastric cancer treatment.

• HER2 is mature, but biosimilar share keeps rising.
• KANJINTI supports Amgen Inc. oncology scale.
• Best fit: Star in the BCG Matrix.

Otezla is a mature cash cow for Amgen: the immune-dermatology brand has a large installed base in psoriasis and psoriatic arthritis, and Amgen reported about $2.0 billion in Otezla sales in 2024. The market is crowded, but demand stays steady, so it keeps throwing off dependable cash instead of chasing growth.

• 2014 launch; durable brand equity
• Psoriasis and PsA remain core uses
• ~$2.0B 2024 sales for Amgen
• Mature market, steady cash generation

In BCG terms, Otezla fits the Cash Cow bucket because it still monetizes a proven franchise with limited need for heavy reinvestment. Its role is to fund Amgen's newer growth assets while defending share in a mature, competitive category.

Nplate, launched in 2008, is an established immune thrombocytopenia (ITP) therapy in a specialized hematology niche. Its long market history and recurring treatment need support steady demand, while growth is likely modest because the franchise is mature, not new.

• 2008 launch; 17-year franchise by 2025
• Specialized ITP market with recurring use
• Stable demand supports Cash Cow status

Sensipar/Mimpara is a mature CKD mineral-bone brand with long-running generic and competitive pressure, so Amgen has little room left to expand it. In BCG terms, that means low growth and weak strategic priority, which is classic Dog territory. Capital is better directed to higher-growth assets.

• Low growth, mature category
• Heavy generic competition
• Limited expansion potential
• Fits Dog in BCG Matrix

Vectibix, launched in 2006, remains a niche EGFR therapy for KRAS wild-type metastatic colorectal cancer. Its market is crowded, and growth is far slower than newer oncology launches. That mix of low share and modest growth fits the Dog quadrant in Amgen Inc.'s BCG view.

• Specialized colorectal cancer use
• Competitive, mature market
• Low share, limited growth
• Dog quadrant fit

Tavneos, launched in 2021 for ANCA-associated vasculitis, targets a rare disease with roughly 40 to 60 cases per million people each year, so its patient pool is small but expandable. Adoption is still building, and Amgen has not turned it into a mature cash engine yet, which fits a Question Mark in the BCG Matrix.

• 2021 launch in a rare autoimmune niche
• Small current brand, still growing uptake
• Expansion potential, but not a cash cow

AMG 193 is a phase 1 PRMT5 inhibitor for precision oncology, so it fits Amgen Inc. as a Question Mark: high upside if data hold, but no commercial share yet. Early assets like this can target a large biomarker-defined pool, yet value still depends on proof of response, safety, and dose. In BCG terms, it is promise plus uncertainty.

• Phase 1 only, no sales yet
• High-risk, high-upside oncology bet